RNA: The new revolution in nucleic acid vaccines

被引：140

作者：

Geall, Andrew J. ^{[1
]}

Mandl, Christian W. ^{[1
]}

Ulmer, Jeffrey B. ^{[1
]}

机构：

[1] Novartis Vaccines & Diagnost, Cambridge, MA 02139 USA

来源：

SEMINARS IN IMMUNOLOGY | 2013年 / 25卷 / 02期

关键词：

Replicon; Manufacturing; Safety; Stability; Human; REVERSE CAP ANALOGS; RABIES VIRUS GLYCOPROTEIN; CYTOTOXIC T-LYMPHOCYTES; MODIFIED MESSENGER-RNA; INFLUENZA-A VIRUS; IMMUNE-RESPONSES; ALPHAVIRUS VECTORS; DNA VACCINES; IN-VIVO; DIRECT-INJECTION;

D O I：

10.1016/j.smim.2013.05.001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Nucleic acid vaccines have the potential to address issues of safety and effectiveness sometimes associated with vaccines based on live attenuated viruses and recombinant viral vectors. In addition, methods to manufacture nucleic acid vaccines are suitable as generic platforms and for rapid response, both of which will be very important for addressing newly emerging pathogens in a timely fashion. Plasmid DNA is the more widely studied form of nucleic acid vaccine and proof of principle in humans has been demonstrated, although no licensed human products have yet emerged. The RNA vaccine approach, based on mRNA and engineered RNA replicons derived from certain RNA viruses, is gaining increased attention and several vaccines are under investigation for infectious diseases, cancer and allergy. Human clinical trials are underway and the prospects for success are bright. (c) 2013 Elsevier Ltd. All rights reserved.

引用

页码：152 / 159

页数：8

共 120 条

[1] Humoral and cellular immune response to RNA immunization with flavivirus Replicons derived from tick-borne encephalitis virus [J].

Aberle, JH ;

Aberle, SW ;

Kofler, RA ;

Mandl, CW .

JOURNAL OF VIROLOGY, 2005, 79 (24) :15107-15113

[2] UU/UA Dinucleotide Frequency Reduction in Coding Regions Results in Increased mRNA Stability and Protein Expression [J].

Al-Saif, Maher ;

Khabar, Khalid S. A. .

MOLECULAR THERAPY, 2012, 20 (05) :954-959

[3] Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation [J].

Anderson, Bart R. ;

Muramatsu, Hiromi ;

Nallagatla, Subba R. ;

Bevilacqua, Philip C. ;

Sansing, Lauren H. ;

Weissman, Drew ;

Kariko, Katalin .

NUCLEIC ACIDS RESEARCH, 2010, 38 (17) :5884-5892

[4]

Atkins Gregory J., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000859

[5] Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers [J].

Bernstein, David I. ;

Reap, Elizabeth A. ;

Katen, Kevin ;

Watson, Aubrey ;

Smith, Kaitlin ;

Norberg, Pamela ;

Olmsted, Robert A. ;

Hoeper, Amy ;

Morris, John ;

Negri, Sarah ;

Maughan, Maureen F. ;

Chulay, Jeffrey D. .

VACCINE, 2009, 28 (02) :484-493

[6] Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells [J].

Bettinger, T ;

Carlisle, RC ;

Read, ML ;

Ogris, M ;

Seymour, LW .

NUCLEIC ACIDS RESEARCH, 2001, 29 (18) :3882-3891

[7] Engineering Dendritic Cells to Enhance Cancer Immunotherapy [J].

Boudreau, Jeanette E. ;

Bonehill, Aude ;

Thielemans, Kris ;

Wan, Yonghong .

MOLECULAR THERAPY, 2011, 19 (05) :841-853

[8]

Breckenridge NC, 2000, BIOTECHNOL BIOENG, V69, P679, DOI 10.1002/1097-0290(20000920)69:6<679::AID-BIT12>3.0.CO

[9]

2-6

[10] HuR and mRNA stability [J].

Brennan, CM ;

Steitz, JA .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (02) :266-277

← 1 2 3 4 5 6 7 8 9 10 →